GSK receives FDA approval for Benlysta autoinjector for lupus treatment, marking significant milestone

From Yahoo Finance: 2025-06-28 12:39:00

GSK plc (NYSE:GSK) receives FDA approval for 200 mg/mL autoinjector of Benlysta for lupus nephritis treatment in children aged five and above. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody, offering a new at-home treatment option for patients and caregivers.

The Benlysta autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. This approval marks a significant milestone, as Benlysta is the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population.

GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company known for researching, developing, and selling medicines and vaccines for various diseases. Key products include Shingrix, Nucala, and HIV treatments through its ViiV Healthcare joint venture, positioning it as a leader in the healthcare industry.

While GSK offers potential as an investment, certain AI stocks may provide greater upside potential with less downside risk. For those interested in undervalued AI stocks with growth potential, consider exploring the best short-term AI stock for investment opportunities in the current market.

Read more: GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment